CELLULARLINE SPA (CELL.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:CELL - IT0005244618 - Common Stock
2.5 EUR
+0.01 (+0.4%)
Taking everything into account, CELL scores 5 out of 10 in our fundamental rating. CELL was compared to 33 industry peers in the Technology Hardware, Storage & Peripherals industry. While CELL has a great health rating, its profitability is only average at the moment. CELL is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CELL was profitable.
In the past year CELL had a positive cash flow from operations.
In multiple years CELL reported negative net income over the last 5 years.
In the past 5 years CELL always reported a positive cash flow from operatings.
1.2 Ratios
CELL has a Return On Assets of 2.60%. This is comparable to the rest of the industry: CELL outperforms 54.55% of its industry peers.
CELL has a Return On Equity of 4.27%. This is in the better half of the industry: CELL outperforms 63.64% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.42%, CELL is in line with its industry, outperforming 48.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 4.27% | ||
| ROIC | 4.42% |
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CELL has a Profit Margin (3.44%) which is in line with its industry peers.
CELL's Profit Margin has declined in the last couple of years.
CELL has a Operating Margin of 4.91%. This is comparable to the rest of the industry: CELL outperforms 57.58% of its industry peers.
CELL's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 40.07%, CELL is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of CELL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.91% | ||
| PM (TTM) | 3.44% | ||
| GM | 40.07% |
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CELL is destroying value.
CELL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CELL has been reduced compared to 5 years ago.
The debt/assets ratio for CELL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.33 indicates that CELL is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of CELL (2.33) is better than 60.61% of its industry peers.
The Debt to FCF ratio of CELL is 2.46, which is a good value as it means it would take CELL, 2.46 years of fcf income to pay off all of its debts.
CELL has a Debt to FCF ratio of 2.46. This is in the better half of the industry: CELL outperforms 72.73% of its industry peers.
CELL has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.13, CELL belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | 2.46 | ||
| Altman-Z | 2.33 |
ROIC/WACC0.52
WACC8.54%
2.3 Liquidity
A Current Ratio of 2.12 indicates that CELL has no problem at all paying its short term obligations.
CELL has a Current ratio of 2.12. This is in the better half of the industry: CELL outperforms 63.64% of its industry peers.
CELL has a Quick Ratio of 1.33. This is a normal value and indicates that CELL is financially healthy and should not expect problems in meeting its short term obligations.
CELL has a better Quick ratio (1.33) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.33 |
3. Growth
3.1 Past
CELL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.78%, which is quite impressive.
CELL shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -20.43% yearly.
Looking at the last year, CELL shows a small growth in Revenue. The Revenue has grown by 3.54% in the last year.
The Revenue has been growing slightly by 3.18% on average over the past years.
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
3.2 Future
The Earnings Per Share is expected to grow by 2.47% on average over the next years.
The Revenue is expected to decrease by -0.60% on average over the next years.
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.69%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.62, the valuation of CELL can be described as reasonable.
Based on the Price/Earnings ratio, CELL is valued cheaply inside the industry as 87.88% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.31, CELL is valued rather cheaply.
With a Price/Forward Earnings ratio of 5.84, the valuation of CELL can be described as very cheap.
93.94% of the companies in the same industry are more expensive than CELL, based on the Price/Forward Earnings ratio.
CELL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 5.84 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CELL is valued cheaper than 93.94% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CELL is valued cheaper than 96.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.67 | ||
| EV/EBITDA | 2.92 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CELL has a Yearly Dividend Yield of 3.77%.
Compared to an average industry Dividend Yield of 2.16, CELL pays a better dividend. On top of this CELL pays more dividend than 90.91% of the companies listed in the same industry.
CELL's Dividend Yield is rather good when compared to the S&P500 average which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.77% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
CELL pays out 34.37% of its income as dividend. This is a sustainable payout ratio.
DP34.37%
EPS Next 2Y2.47%
EPS Next 3YN/A
BIT:CELL (11/25/2025, 5:29:46 PM)
2.5
+0.01 (+0.4%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners5.79%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap54.67M
Revenue(TTM)164.26M
Net Income(TTM)5.65M
Analysts82.86
Price Target4.18 (67.2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.77% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP34.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-28.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 5.84 | ||
| P/S | 0.33 | ||
| P/FCF | 3.67 | ||
| P/OCF | 2.69 | ||
| P/B | 0.41 | ||
| P/tB | 1 | ||
| EV/EBITDA | 2.92 |
EPS(TTM)0.26
EY10.4%
EPS(NY)0.43
Fwd EY17.14%
FCF(TTM)0.68
FCFY27.28%
OCF(TTM)0.93
OCFY37.13%
SpS7.51
BVpS6.05
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 4.27% | ||
| ROCE | 5.04% | ||
| ROIC | 4.42% | ||
| ROICexc | 5.33% | ||
| ROICexgc | 12.93% | ||
| OM | 4.91% | ||
| PM (TTM) | 3.44% | ||
| GM | 40.07% | ||
| FCFM | 9.08% |
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y46.34%
ROICexgc growth 5Y-17.53%
ROICexc growth 3Y77.77%
ROICexc growth 5Y-8.95%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
F-Score4
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | 2.46 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 39.19% | ||
| Cap/Sales | 3.28% | ||
| Interest Coverage | 2.77 | ||
| Cash Conversion | 93.13% | ||
| Profit Quality | 264.18% | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | 2.33 |
F-Score4
WACC8.54%
ROIC/WACC0.52
Cap/Depr(3y)26.8%
Cap/Depr(5y)35.01%
Cap/Sales(3y)3.22%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
Revenue Next Year-5.69%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.25%
EBIT growth 3Y54.08%
EBIT growth 5Y-17%
EBIT Next Year28.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1050.19%
FCF growth 3Y4.84%
FCF growth 5Y6.28%
OCF growth 1Y730.91%
OCF growth 3Y4.12%
OCF growth 5Y1.2%
CELLULARLINE SPA / CELL.MI FAQ
What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.
What is the valuation status of CELLULARLINE SPA (CELL.MI) stock?
ChartMill assigns a valuation rating of 7 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Undervalued.
What is the profitability of CELL stock?
CELLULARLINE SPA (CELL.MI) has a profitability rating of 4 / 10.
How financially healthy is CELLULARLINE SPA?
The financial health rating of CELLULARLINE SPA (CELL.MI) is 7 / 10.
What is the expected EPS growth for CELLULARLINE SPA (CELL.MI) stock?
The Earnings per Share (EPS) of CELLULARLINE SPA (CELL.MI) is expected to decline by -12.5% in the next year.